BACKGROUND: As important mediators of solute transport at the blood-brain and blood-cerebrospinal fluid barriers, ATP-binding cassette (ABC) transporters (including ABCB1, ABCC1, and ABCC2), impact the bioavailability of drugs and endogenous substrates in the brain. While several ABCB1, ABCC1, and ABCC2 single nucleotide polymorphisms (SNPs) have been identified, their impact on outcome after traumatic brain injury (TBI) is unknown. HYPOTHESIS: ABCB1, ABCC1, and ABCC2 SNPs are associated with Glasgow Outcome Scale (GOS) score after TBI. METHODS: DNA samples from 305 adult patients with severe TBI (Glasgow Coma Scale, GCS score ≤ 8) were genotyped for tagging SNPs of ABCB1 (rs1045642; rs1128503), ABCC1 (rs212093; rs35621; rs4148382), and ABCC2 (rs2273697). For each SNP, patients were dichotomized based on presence of variant allele for multivariate analysis to determine associations with GOS assigned at 6 months adjusting for GCS, Injury Severity score, age, and patient sex. RESULTS: For ABCB1 rs1045642, patients homozygous for the T allele were less likely to be assigned poor outcome versus those possessing the C allele [CT/CC; odds of unfavorable GOS = 0.71(0.55-0.92)]. For ABCC1 rs4148382, patients homozygous for the G allele were less likely to be assigned poor outcome versus those possessing the A allele [AG/AA; odds of unfavorable GOS = 0.73(0.55-0.98)]. CONCLUSIONS: In this single-center study, patients homozygous for the T allele of ABCB1 rs1045642 or the G allele of ABCC1 rs4148382 were found to have better outcome after severe TBI. Further study is necessary to replicate these very preliminary findings and to determine whether these associations are due to central nervous system bioavailability of ABC transporter drug substrates commonly used in the management of TBI, brain efflux of endogenous solutes, or both.
BACKGROUND: As important mediators of solute transport at the blood-brain and blood-cerebrospinal fluid barriers, ATP-binding cassette (ABC) transporters (including ABCB1, ABCC1, and ABCC2), impact the bioavailability of drugs and endogenous substrates in the brain. While several ABCB1, ABCC1, and ABCC2 single nucleotide polymorphisms (SNPs) have been identified, their impact on outcome after traumatic brain injury (TBI) is unknown. HYPOTHESIS: ABCB1, ABCC1, and ABCC2 SNPs are associated with Glasgow Outcome Scale (GOS) score after TBI. METHODS: DNA samples from 305 adult patients with severe TBI (Glasgow Coma Scale, GCS score ≤ 8) were genotyped for tagging SNPs of ABCB1 (rs1045642; rs1128503), ABCC1 (rs212093; rs35621; rs4148382), and ABCC2 (rs2273697). For each SNP, patients were dichotomized based on presence of variant allele for multivariate analysis to determine associations with GOS assigned at 6 months adjusting for GCS, Injury Severity score, age, and patient sex. RESULTS: For ABCB1 rs1045642, patients homozygous for the T allele were less likely to be assigned poor outcome versus those possessing the C allele [CT/CC; odds of unfavorable GOS = 0.71(0.55-0.92)]. For ABCC1rs4148382, patients homozygous for the G allele were less likely to be assigned poor outcome versus those possessing the A allele [AG/AA; odds of unfavorable GOS = 0.73(0.55-0.98)]. CONCLUSIONS: In this single-center study, patients homozygous for the T allele of ABCB1 rs1045642 or the G allele of ABCC1rs4148382 were found to have better outcome after severe TBI. Further study is necessary to replicate these very preliminary findings and to determine whether these associations are due to central nervous system bioavailability of ABC transporter drug substrates commonly used in the management of TBI, brain efflux of endogenous solutes, or both.
Authors: Asra Siddiqui; Reinhold Kerb; Michael E Weale; Ulrich Brinkmann; Alice Smith; David B Goldstein; Nicholas W Wood; Sanjay M Sisodiya Journal: N Engl J Med Date: 2003-04-10 Impact factor: 91.245
Authors: Andrew Owen; Chris Goldring; Paul Morgan; David Chadwick; B Kevin Park; Munir Pirmohamed Journal: Br J Clin Pharmacol Date: 2005-03 Impact factor: 4.335
Authors: S Hoffmeyer; O Burk; O von Richter; H P Arnold; J Brockmöller; A Johne; I Cascorbi; T Gerloff; I Roots; M Eichelbaum; U Brinkmann Journal: Proc Natl Acad Sci U S A Date: 2000-03-28 Impact factor: 11.205
Authors: F Anthony Willyerd; Philip E Empey; Ashley Philbrick; Milos D Ikonomovic; Ava M Puccio; Patrick M Kochanek; David O Okonkwo; Robert S B Clark Journal: J Neurotrauma Date: 2015-06-17 Impact factor: 5.269
Authors: Fanuel T Hagos; Solomon M Adams; Samuel M Poloyac; Patrick M Kochanek; Christopher M Horvat; Robert S B Clark; Philip E Empey Journal: Exp Neurol Date: 2019-02-21 Impact factor: 5.330
Authors: Solomon M Adams; Yvette P Conley; Dianxu Ren; David O Okonkwo; Ava M Puccio; C Edward Dixon; Robert S B Clark; Patrick M Kochanek; Philip E Empey Journal: J Neurotrauma Date: 2017-09-19 Impact factor: 5.269
Authors: Ruchira M Jha; Ava M Puccio; David O Okonkwo; Benjamin E Zusman; Seo-Young Park; Jessica Wallisch; Philip E Empey; Lori A Shutter; Robert S B Clark; Patrick M Kochanek; Yvette P Conley Journal: Neurocrit Care Date: 2017-04 Impact factor: 3.210
Authors: Solomon M Adams; Yvette P Conley; Amy K Wagner; Ruchira M Jha; Robert Sb Clark; Samuel M Poloyac; Patrick M Kochanek; Philip E Empey Journal: Pharmacogenomics Date: 2017-10-04 Impact factor: 2.533
Authors: Christopher M Horvat; Alicia K Au; Yvette P Conley; Patrick M Kochanek; Lingjue Li; Samuel M Poloyac; Philip E Empey; Robert S B Clark Journal: Pediatr Res Date: 2017-05-31 Impact factor: 3.756
Authors: Margaret J Ochocinska; Berislav V Zlokovic; Peter C Searson; A Tamara Crowder; Richard P Kraig; Julia Y Ljubimova; Todd G Mainprize; William A Banks; Ronald Q Warren; Andrei Kindzelski; William Timmer; Christina H Liu Journal: Fluids Barriers CNS Date: 2017-05-01
Authors: Frederick A Zeiler; Charles McFadyen; Virginia F J Newcombe; Anneliese Synnot; Emma L Donoghue; Samuli Ripatti; Ewout W Steyerberg; Russel L Gruen; Thomas W McAllister; Jonathan Rosand; Aarno Palotie; Andrew I R Maas; David K Menon Journal: J Neurotrauma Date: 2019-06-07 Impact factor: 5.269